These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12192774)

  • 1. Managing technological explosion in the medical management of coronary artery disease, Part II. DES economic modeling: budgeting strategies for drug-eluting stent technology.
    Chumer K; DeCerce J; Vaul J
    J Cardiovasc Manag; 2002; 13(4):16-20. PubMed ID: 12192774
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing technological explosion in the medical management of coronary artery disease. Cardiovascular administrators are key internal consultants in planning for drug-eluting stent technology.
    DeCerce J; Chumer K
    J Cardiovasc Manag; 2002; 13(3):13-6. PubMed ID: 12048868
    [No Abstract]   [Full Text] [Related]  

  • 3. One-year clinical results and total costs of drug-eluting stents implantation in multivessel coronary artery disease.
    Varani E; Balducelli M; Vecchi G; Aquilina M; Maresta A
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):596-601. PubMed ID: 17667030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of efficacy and cost-effectiveness of drug-eluting stents.
    Lyratzopoulos G
    Eur Heart J; 2006 Dec; 27(24):3075-6; author reply 3076. PubMed ID: 17127710
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.
    Goeree R; Bowen JM; Blackhouse G; Lazzam C; Cohen E; Chiu M; Hopkins R; Tarride JE; Tu JV
    Int J Technol Assess Health Care; 2009 Apr; 25(2):196-207. PubMed ID: 19331710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of drug-eluting stents on hospital systems: a disease-state model.
    Kong DF; Eisenstein EL; Sketch MH; Zidar JP; Ryan TJ; Harrington RA; Newman MF; Smith PK; Mark DB; Califf RM
    Am Heart J; 2004 Mar; 147(3):449-56. PubMed ID: 14999193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-eluting stent task force: final report and recommendations of the working committees on cost-effectiveness/economics, access to care, and medicolegal issues.
    Hodgson JM; Bottner RK; Klein LW; Walpole HT; Cohen DJ; Cutlip DE; Fenninger RB; Firth BG; Greenberg D; Kalisky I; Meskan T; Powell W; Stone GW; Zito JP; Clark MA
    Catheter Cardiovasc Interv; 2004 May; 62(1):1-17. PubMed ID: 15103593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The costs of drug-eluting coronary stents among Medicare beneficiaries.
    Groeneveld PW; Matta MA; Greenhut AP; Yang F
    Am Heart J; 2008 Jun; 155(6):1097-105. PubMed ID: 18513525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost comparison of four revascularisation procedures for the treatment of multivessel coronary artery disease.
    Wang X; Rokoss M; Dyub A; Gafni A; Lamy A
    J Med Econ; 2008; 11(1):119-34. PubMed ID: 19450114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance.
    Messori A; Trippoli S
    Heart; 2009 May; 95(10):847. PubMed ID: 19401286
    [No Abstract]   [Full Text] [Related]  

  • 12. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
    Daemen J; Simoons ML; Wijns W; Bagust A; Bos G; Bowen JM; Braunwald E; Camenzind E; Chevaliers B; DiMario C; Fajadeto J; Gitt A; Guagliumi G; Hillege HL; James S; Jüni P; Kastrati A; Kloth S; Kristensen SD; Krucoff M; Legrand V; Pfisterer M; Rothman M; Serruys PW; Silber S; Steg PG; Tariah I; Wallentin L; Windecker SW; Aimonetti A; Allocco D; Berenger M; Boam A; Calle JP; Campo G; Carlier S; de Schepper J; Di Bisceglie G; Dobbels H; Farb A; Ghislain JC; Hellbardt S; ten Hoedt R; Isaia C; de Jong P; Lekehal M; LeNarz L; Mhullain FN; Nagai H; Patteet A; Paunovic D; Potgieter A; Purdy I; Raveau-Landon C; Ternstrom S; Van Wuytswinkel J; Waliszewski M;
    EuroIntervention; 2009 Jan; 4(4):427-36. PubMed ID: 19284063
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug-eluting stents: cost versus clinical benefit.
    Lemos PA; Serruys PW; Sousa JE
    Circulation; 2003 Jun; 107(24):3003-7. PubMed ID: 12821586
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrating new technology with managed care contracting.
    DeCerce J; Kaden RJ; Zupa K
    J Cardiovasc Manag; 1998; 9(Suppl):3-15. PubMed ID: 10181697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Degradable, drug-eluting stents: a new frontier for the treatment of coronary artery disease.
    Kohn J; Zeltinger J
    Expert Rev Med Devices; 2005 Nov; 2(6):667-71. PubMed ID: 16293093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational use of drug-eluting stents: a comparison of different policies.
    Remmel M; Hartmann F; Harland LC; Schunkert H; Radke PW
    Crit Pathw Cardiol; 2007 Jun; 6(2):85-9. PubMed ID: 17667871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system.
    Ekman M; Sjögren I; James S
    Scand Cardiovasc J; 2006 Feb; 40(1):17-24. PubMed ID: 16448993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug-eluting stents: costs versus clinical benefit.
    O'Neill WW; Leon MB
    Circulation; 2003 Jun; 107(24):3008-11. PubMed ID: 12821587
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug-eluting stents.
    Cohen DJ; Bakhai A
    CMAJ; 2007 May; 176(11):1612. PubMed ID: 17515592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.